Pharmacological Properties of ABT-239 [4-(2-{2-[(2 R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties
- 1 April 2005
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 313 (1) , 165-175
- https://doi.org/10.1124/jpet.104.078303
Abstract
Histamine H3 receptor antagonists are being developed to treat a variety of neurological and cognitive disorders that may be ameliorated by enhancement of central neurotransmitter release. Here, we present the in vitro pharmacological and in vivo pharmacokinetic profiles for the nonimidazole, benzofuran ligand ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile] and compare it with several previously described imidazole and nonimidazole H3 receptor antagonists. ABT-239 binds to recombinant human and rat H3 receptors with high affinity, with pKi values of 9.4 and 8.9, respectively, and is over 1000-fold selective versus human H1, H2, and H4 histamine receptors. ABT-239 is a potent H3 receptor antagonist at recombinant human and rat receptors, reversing agonist-induced changes in cAMP formation (pKb = 7.9 and 7.6, respectively), guanosine 5′-O-(3-[35S]thio) triphosphate ([35S]GTPγS) binding (pKb = 9.0 and 8.3, respectively), and calcium mobilization (human pKb = 7.9). ABT-239 also competitively reversed histamine-mediated inhibition of [3H]histamine release from rat brain cortical synaptosomes (pKb = 7.7) and agonist-induced inhibition of contractile responses in electric field stimulated guinea pig ileal segments (pA2 = 8.7). Additionally, ABT-239 is a potent inverse agonist, inhibiting constitutive [35S]GTPγS binding at both rat and human H3 receptors with respective pEC50 values of 8.9 and 8.2. ABT-239 demonstrates good pharmacokinetic characteristics in rat, dog, and monkey with t1/2 values ranging from 4 to 29 h, corresponding with clearance values and metabolic turnover in liver microsomes from these species, and good oral bioavailability ranging from 52 to 89%. Thus, ABT-239 is a selective, nonimidazole H3 receptor antagonist/inverse agonist with similar high potency in both human and rat and favorable drug-like properties.Keywords
This publication has 36 references indexed in Scilit:
- Pharmacological Properties of ABT-239 [4-(2-{2-[(2 R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor AntagonistThe Journal of Pharmacology and Experimental Therapeutics, 2005
- 1-Alkyl-4-acylpiperazines as a New Class of Imidazole-Free Histamine H3 Receptor AntagonistsJournal of Medicinal Chemistry, 2004
- A New Class of Diamine-Based Human Histamine H3 Receptor Antagonists: 4-(Aminoalkoxy)benzylaminesJournal of Medicinal Chemistry, 2003
- Two Novel and Selective Nonimidazole H3 Receptor Antagonists A-304121 and A-317920: II. In Vivo Behavioral and Neurophysiological CharacterizationThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Two Novel and Selective Nonimidazole Histamine H3 Receptor Antagonists A-304121 and A-317920: I. In Vitro Pharmacological EffectsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Novel Nonimidazole Histamine H3 Receptor Antagonists: 1-(4-(Phenoxymethyl)benzyl)piperidines and Related CompoundsJournal of Medicinal Chemistry, 2003
- Distinct pharmacology of rat and human histamine H3 receptors: role of two amino acids in the third transmembrane domainBritish Journal of Pharmacology, 2000
- Characterization of the binding of [3H]-clobenpropit to histamine H3-receptors in guinea-pig cerebral cortex membranesBritish Journal of Pharmacology, 1999
- Highly potent and selective ligands for histamine H3-receptorsNature, 1987
- Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptorNature, 1983